Canadian parent patent and CIP for the use of galantamine as a Method of Treating Organophosphorus Poisoning awarded. October 27, 2015 • admin • General News Read More »
Countervail competes and is selected for participation in the SBIR sponsored Commercialization Acceleration Program (CAP). October 14, 2015 • admin • Funding, General News Read More »